Integra LifeSciences Holdings Corporation

Equities

IART

US4579852082

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq 16:30:01 2024-05-06 EDT 5-day change 1st Jan Change
23.14 USD -19.90% Intraday chart for Integra LifeSciences Holdings Corporation -20.86% -46.87%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Wells Fargo Downgrades Integra LifeSciences Holdings to Equalweight From Overweight, Cuts Price Target to $25 From $45 MT
Oppenheimer Downgrades Integra LifeSciences Holdings to Perform From Outperform MT
Integra LifeSciences Shares Drop to Record Low on Unexpected Loss, Boston Facility Audit Findings DJ
Transcript : Integra LifeSciences Holdings Corporation, Q1 2024 Earnings Call, May 06, 2024
Integra LifeSciences Q1 Adjusted Earnings, Revenue Fall; Updates 2024 Outlook MT
North American Morning Briefing : Stock Futures -2- DJ
Integra LifeSciences Holdings Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Earnings Flash (IART) INTEGRA LIFESCIENCES HOLDINGS CORPORATION Reports Q1 Revenue $368.9M, vs. Street Est of $362M MT
Earnings Flash (IART) INTEGRA LIFESCIENCES HOLDINGS CORPORATION Posts Q1 EPS $0.55, vs. Street Est of $0.55 MT
Integra LifeSciences Holdings Corporation Provides Revenue Guidance for the Second Quarter and Full Year 2024 CI
North American Morning Briefing : Focus Turns to -2- DJ
Citigroup Upgrades Integra LifeSciences to Neutral From Sell With $38 Price Target MT
Citigroup Upgrades Integra LifeSciences to Neutral From Sell, Price Target is $38 MT
Integra LifeSciences Completes Acquisition of Acclarent MT
Integra LifeSciences Holdings Corporation acquired 100% stake in Acclarent, Inc. from Ethicon US, LLC for $280 million. CI
Integra Lifesciences Launches Micromatrix Flex to Provide Convenient Access to Hard-To-Reach Areas in Complex Cases CI
Integra Lifesciences Holdings Insider Sold Shares Worth $305,492, According to a Recent SEC Filing MT
Truist Securities Cuts Price Target on Integra LifeSciences Holdings to $41 From $46, Maintains Hold Rating MT
Tranche Update on Integra LifeSciences Holdings Corporation's Equity Buyback Plan announced on July 27, 2023. CI
Integra LifeSciences Shares Drop Following Q4 Results MT
Integra LifeSciences Seeks Acquisitions CI
Transcript : Integra LifeSciences Holdings Corporation, Q4 2023 Earnings Call, Feb 28, 2024
Integra LifeSciences' Q4 Adjusted Earnings, Revenue Decline MT
Integra LifeSciences Holdings Corporation Announces the Retirement of Jan De Witte as Chief Executive Officer CI
Integra LifeSciences Holdings Corporation Announces Board Changes CI
Chart Integra LifeSciences Holdings Corporation
More charts
Integra LifeSciences Holdings Corporation is a global medical technology company. The Company manufactures and sells medical technologies and products in two segments: Codman Specialty Surgical (CSS) and Tissue Technologies (TT). The CSS segment consists of technologies and instrumentation used for a range of specialties, such as neurosurgery, neurocritical care and otolaryngology. The CSS business consists of a portfolio of brands, such as Codman, DuraGen, DuraSeal, CUSA, Mayfield, Bactiseal, and Certas Plus, which are used for the management of multiple disease states, including brain tumors, traumatic brain injury, hydrocephalus and other neurological conditions. The Company provides instruments that are used in precision, specialty and general surgical procedures. The TT segment is focused on three main areas: complex wound surgery, surgical reconstruction and peripheral nerve repair. The TT segment offers skin and wound repair, bone grafts, and nerve and tendon repair products.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
13
Last Close Price
23.14 USD
Average target price
36.8 USD
Spread / Average Target
+59.03%
Consensus
  1. Stock Market
  2. Equities
  3. IART Stock
  4. News Integra LifeSciences Holdings Corporation
  5. Integra LifeSciences : Credit Suisse Raises Integra LifeSciences Holdings' Price Target to $79 From $73, Keeps Outperform Rating
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW